Gilead Sciences to Acquire Arcellx for $7.8 Billion in Cash and CVRs

summarizeSummary

This Schedule 13D confirms and provides the detailed legal framework for the acquisition of Arcellx by Gilead Sciences, following the concurrent SC TO-C filing. Gilead will acquire all outstanding shares of Arcellx for $115.00 per share in cash, plus a contingent value right (CVR) of $5.00 per share upon achievement of a specified milestone. This represents a significant premium over Arcellx's recent trading price and market capitalization, offering a clear exit for shareholders. Gilead already held an 11.5% stake in Arcellx, built through prior strategic investments in 2023 and 2024, stemming from a collaboration agreement. The acquisition will be executed via a tender offer, followed by a merger, and will result in Arcellx becoming a wholly-owned subsidiary of Gilead and its subsequent delisting from Nasdaq. The Tender and Support Agreements with key shareholders, including directors and officers, representing approximately 10.3% of outstanding shares, underscore the high likelihood of the transaction's completion.

check_boxKey Events

• Definitive Acquisition Agreement

  Gilead Sciences, Inc. will acquire Arcellx, Inc. for approximately $7.8 billion. Shareholders will receive $115.00 per share in cash plus one contingent value right (CVR) worth $5.00 upon milestone achievement.

• Existing Strategic Stake

  Gilead currently holds 6,720,803 shares, representing an 11.5% beneficial ownership stake in Arcellx, acquired through prior stock purchase agreements in 2023 and 2024.

• Tender and Support Agreements

  Key Arcellx shareholders, including directors and officers, collectively owning approximately 10.3% of outstanding shares, have entered into agreements to tender their shares in the offer.

• Planned Delisting

  Following the merger, Arcellx will become a wholly-owned subsidiary of Gilead, and its shares will be delisted from the Nasdaq Global Select Market.

auto_awesomeAnalysis

This Schedule 13D confirms and provides the detailed legal framework for the acquisition of Arcellx by Gilead Sciences, following the concurrent SC TO-C filing. Gilead will acquire all outstanding shares of Arcellx for $115.00 per share in cash, plus a contingent value right (CVR) of $5.00 per share upon achievement of a specified milestone. This represents a significant premium over Arcellx's recent trading price and market capitalization, offering a clear exit for shareholders. Gilead already held an 11.5% stake in Arcellx, built through prior strategic investments in 2023 and 2024, stemming from a collaboration agreement. The acquisition will be executed via a tender offer, followed by a merger, and will result in Arcellx becoming a wholly-owned subsidiary of Gilead and its subsequent delisting from Nasdaq. The Tender and Support Agreements with key shareholders, including directors and officers, representing approximately 10.3% of outstanding shares, underscore the high likelihood of the transaction's completion.